CINECA IRIS Institutional Research Information System

CASCIO, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.340
EU - Europa 2.421
AS - Asia 1.012
AF - Africa 94
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 1
Totale 6.893
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.296
IT - Italia 625
CN - Cina 502
IE - Irlanda 330
SE - Svezia 263
FR - Francia 214
SG - Singapore 208
FI - Finlandia 197
UA - Ucraina 191
DE - Germania 168
KR - Corea 147
PL - Polonia 112
DK - Danimarca 108
GB - Regno Unito 105
SN - Senegal 88
VN - Vietnam 58
CA - Canada 44
AT - Austria 43
ID - Indonesia 28
RU - Federazione Russa 21
IN - India 18
BE - Belgio 15
HK - Hong Kong 15
JP - Giappone 14
NL - Olanda 12
AU - Australia 11
EU - Europa 11
TW - Taiwan 9
ES - Italia 6
IL - Israele 5
CH - Svizzera 3
CZ - Repubblica Ceca 3
IR - Iran 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
RO - Romania 3
AE - Emirati Arabi Uniti 1
BR - Brasile 1
DZ - Algeria 1
EG - Egitto 1
GR - Grecia 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
PH - Filippine 1
RS - Serbia 1
TH - Thailandia 1
TR - Turchia 1
Totale 6.893
Salva come PNG Salva come JPEG
Città #
Chandler 372
Beijing 356
Dublin 330
Fairfield 232
Houston 174
Ann Arbor 156
Singapore 150
Torino 147
Villeurbanne 139
Ashburn 137
Santa Clara 129
Dearborn 118
Medford 111
Jacksonville 109
Warsaw 108
Woodbridge 106
Nyköping 104
Wilmington 104
Princeton 101
Columbus 93
Seattle 71
Pisa 56
New York 49
Cambridge 46
Milan 45
Vienna 40
Boston 39
Dong Ket 30
Jakarta 28
Guangzhou 24
Toronto 24
Los Angeles 17
Norwalk 17
Rome 17
Boardman 16
Nanjing 16
Redwood City 16
San Diego 16
Turin 16
Fremont 14
Shanghai 14
Falls Church 13
Mountain View 12
Verona 12
Hefei 11
Naples 11
Brussels 10
San Francisco 8
Helsinki 7
Lachine 7
San Mateo 7
Bari 6
Detroit 6
Hebei 6
Kunming 6
Philadelphia 6
Saint Petersburg 6
Silver Spring 6
Buffalo 5
Hong Kong 5
Melbourne 5
Munich 5
Ottawa 5
Phoenix 5
Atlanta 4
Heidelberg 4
London 4
Mauguio 4
Natick 4
Parma 4
Pune 4
Seoul 4
Stockholm 4
Trieste 4
Trofarello 4
Acerra 3
Brescia 3
Central District 3
Chengdu 3
Chongqing 3
Fuzhou 3
Hangzhou 3
Jinan 3
Lyons 3
Mondolfo 3
Monrovia 3
Nanchang 3
Nuremberg 3
Pavia 3
Shenzhen 3
Upper Marlboro 3
Almora 2
Anghiari 2
Aurora 2
Bergamo 2
Bologna 2
Brighton 2
Capua 2
Changsha 2
Como 2
Totale 4.167
Salva come PNG Salva come JPEG
Nome #
Studio dei proteasomi come potenziali target molecolari di nuove terapie contro il Mesotelioma Pleurico Maligno 229
Comparative study of the biochemical properties of proteasomes in domestic animals 198
Identificazione dei meccanismi molecolari responsabili della sensibilità del mieloma multiplo all’azione pro-apoptotica degli inibitori del proteasoma 181
Low proviral Small Ruminant Lentivirus load as biomarker of natural restriction in goats 171
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 164
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells 161
A Quantitative Method to Monitor the Efficacy of Inhibitors Against the Chymotrypsin-Like Activity of the Proteasome in Tobacco Leaf Protoplasts 147
The direction of protein entry into the proteasome determines the variety of products and depends on the force needed to unfold its two termini 142
PA28ab Reduces Size and Increases Hydrophilicity of 20S Immunoproteasome Peptide Products 142
MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. 128
Enhanced rate of degradation of basic proteins by 26S immunoproteasomes. 123
Alterations of the MCH class-I antigen presentation pathway in feline injection-site sarcoma (FISS) 122
Studio della struttura e delle funzioni del PA28 attivatore del proteosoma 115
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis 115
Immunological parameters in goats experimentaly infected with SRLV genotype E, strain Roccaverano. 115
Proteasomes are not a target for doxorubicin in feline injection-site sarcoma 113
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition 103
Affinity purification and characterization of protein gene product 9.5 (PGP9.5) from retina. 102
A new fluorogenic peptide determines proteasome activity in single cells 98
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis 92
Enhanced expression of γ-interferon induced antigen-processing machinery components in a spontaneously occurring cancer 91
Proteasome stress sensitizes malignant pleural mesothelioma cells to Bortezomib-induced apoptosis. 90
Catalytic, immunochemical and molecular characterization of xenobiotic-metabolising enzyme modulation by phenobarbital in the bovine liver 89
Enhanced expression of gamma-interferon induced antigen processing machinery components in feline-injection site sarcoma 87
Parametri immunologici in capre sperimentalmente infettate con Lentivirus dei Piccoli Ruminanti, genotipo E, stipite Roccaverano 85
Study on the stat1 expression in preoperatively doxorubicin treated feline injection-site sarcoma (FISS) 83
Correlation between proteasomes activity, clinical behaviour and histopathological grading in feline and canine malignantspontaneous tumours 78
Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome 75
Studio strutturale e funzionale dell'attivatore dei proteasomi PA28 73
Analisi dell’attività proteasomale come marker per lo studio delle neoplasie 73
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide 72
Distinct Proteolytic Processes Generate the C and N Termini of MHC Class I-binding Peptides 70
Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases 69
Impaired Proteasomal Capacity and ER Stress as Therapeutic Targets Against Multiple Myeloma 68
Proteasomes are not a target of doxorubicin in feline-injection site sarcoma 66
The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes 66
Assessing proteostasis and proteasome stress in light chain amyloidosis 66
The Axial Channel of the Proteasome Core Particle Is Gated by Rpt2 ATPase and Controls Both Substrate Entry and Product Release 65
Progressively impaired proteosomal capacity limits plasma cell lifespan 65
Direct Assessment of Proteasomal Degradation as a Potential Predictor of Responsiveness to Bortezomib in Multiple Myeloma 63
Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: A proof of concept for novel combination therapies 63
Progressively impaired proteosomal capacity limits plasma cell lifespan 62
Investigating vulnerability to proteasome inhibition in primary light chain amyloidosis 62
Proteasome decrease during plasma cell differentiation in vivo enables to blunt Ab responses with proteasome inhibitors 61
Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3 61
Assessing proteasome workload to predict response and overcome resistance to proteasome inhibitors in multiple myeloma 60
Generation of cellular and animal models to monitor the role of the unfolded protein response in development and genetic diseases 59
Proteasome levels and activities increase in canine mammary tumors 59
Study on the stati expression in preoperatively doxorubicin treated feline injection-site sarcoma (Fiss) 58
The Load vs. Capacity model: a quantitative approach to understand the exquisite sensitivity of plasma cells to proteasome inhibitors 58
Preparation of hybrid (19S-20S-PA28) proteasome complexes and analysis of peptides generated during protein degradation 58
Dampening Ab responses using proteasome inhibitors following in vivo B cell activation 58
The Proteasomes as complex integrators of stress signals and death responses in canine osteosarcoma: their role as potential molecular targets of new anti-cancer therapies 57
Bases of sensitivity of light chain amyloidosis to proteasome inhibitors: assessing proteostasis and proteasome stress 57
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors 56
Increase in Proteasome levels and activities in Feline Injection-Site Sarcomas 56
Effect of the load versus capacity unbalance on the sensitivity of malignant pleural mesothelioma cells to proteasome inhibitors 56
Ruolo dei proteosomi nelle risposte immunitarie cellulo-mediate, nei processi di differenziazione dei linfociti B e nella patogenesi della Sclerosi Laterale Amiotrofica 55
Comparative study of proteasomal enzymatic activities in farm animals to better understand biochemical mechanisms of antigen processing 55
A new fluorogenic peptide determines proteasome activity in single cells 54
Identification of potential new MHC-I epitopes through in vitro proteasomal degradation of antigenic proteins 54
Role of the apelinergic pathway in colon adenocarcinoma-induced muscle wasting 54
Progressively impaired proteasomal capacity limits plasma cell lifespan 53
Proteasome activity and stress in light chain amyloidosis 53
The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides 52
Doxorubicin treatment does not affect enhanced immunoproteasome expression and activities in feline-injection site sarcoma 52
In vitro degradation of survivin with 26S proteasome to identify potential new MHC-I antigenic peptides 52
Immunohistochemical study of STAT3 expression in feline injection-site fibrosarcomas 52
Ubiquitinated aggregates in a transgenic mouse model of familial amyotrophic lateral sclerosis: mechanisms of formation and proteomic characterization 51
Imbalance between synthetic load and proteasomal capacity as the target of proteasome inhibitors in multiple myeloma 51
The Enigmatic Magic Ring of the Proteasome? 51
BIOCHEMICAL CHARACTERIZATION OF 26S PROTEASOMES IN FARM ANIMALS TO IMPROVE KNOWLEDGE ABOUT ANTIGEN PROCESSING 50
PA28αβ Reduces Size and Increases Hydrophilicity of 20S Immunoproteasome Peptide Products 49
The role of ERAD in plant cells: a preliminary biochemical characterization of plant proteasomes 48
Role of dysfunction of the ubiquitin proteasome pathway in the mechanisms of motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis 47
Electron microscopy and functional studies reveal cellular stress in amyloidogenic plasma cells 47
Electron microscopy and functional studies reveal cellular stress in amyloidogenic plasma cells 47
Induction by Phenobarbital of Phase I and II Xenobiotic-Metabolizing Enzymes in Bovine Liver: An Overall Catalytic and Immunochemical Characterization 46
Studies on hSOD-1 accumulation and on the ubiquitin/proteasome pathway in a murine model of amyotrophic lateral sclerosis 44
Progressively impaired proteasomal capacity during terminal plasma cell differentiation 43
The load versus capacity unbalance sensitizes Malignant Pleural Mesothelioma cells to proteasome inhibitors 42
New methods to improve in vitro proteasomal degradation of the universal tumor antigene Survivin and to identify potential new MHC-I epitopes 42
Lentiviral vector gene transfer is limited by the proteasome at post-entry steps in various types of stem cells 41
In vitro proteasomal degradation of antigenic proteins to identify potential new MHC-I epitopes 41
Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction 40
Studio strutturale e funzionale dei proteasomi 20S e 26S nelle cellule vegetali con particolare riferimento al lororuolo nel processo di Degradazione Associata all’ER (ERAD) 40
Proteasome stress causes apoptotic sensitivity of multiple myeloma cells to proteasome inhibition 40
Impaired proteasomal capacity as the target of proteasome inhibitors in multiple myeloma 39
The Load vs. Capacity model: a quantitative approach to understand the exquisite sensitivity of plasma cells to proteasome inhibitors 38
Inherent cellular stress and exquisite proteasome sensitivity in amyloidogenic plasma cells 37
PA28γ–20S proteasome is a proteolytic complex committed to degrade unfolded proteins 37
Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes 36
I tumori spontanei negli animali come modelli di studio per l'oncologia comparata 35
Studies on hSOD-1 accumulation and on the ubiquitin/proteasome pathway in a murine model of amyotrophic lateral sclerosis 33
Orthopaedic surgery in multiple myeloma: from palliation to basic cancer research 33
Imbalance between synthetic load and proteasomal capacity sensitizes normal and malignant plasma cells to proteasome inhibitors 31
PA28αβ-induced modifications in the patterns of peptides produced by proteasomes from full length protein substrates 31
A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose 29
Pa28γ: New insights on an ancient proteasome activator 28
Proteasome insufficiency, counteracted by autophagy, is causal to the death of antibody secreting cells. Keystone Symposia on Cell Death in the Immune System 25
Totale 7.134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.943
article - articoli 0
book - libri 0
conference - conferenze 9.979
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020727 0 0 0 0 66 145 142 58 97 95 81 43
2020/2021760 98 34 41 35 69 41 81 34 101 91 35 100
2021/2022822 44 29 34 47 28 36 74 29 36 56 176 233
2022/20231.227 149 92 28 99 116 315 139 60 113 32 54 30
2023/2024542 72 108 21 34 31 75 12 11 4 30 45 99
2024/2025553 21 78 47 143 264 0 0 0 0 0 0 0
Totale 7.201